Thirty years of hemophilia treatment in the Netherlands, 1972-2001
- PMID: 15308570
- DOI: 10.1182/blood-2004-05-2008
Thirty years of hemophilia treatment in the Netherlands, 1972-2001
Abstract
Since the introduction of replacement therapy in the early 1960s by the infusion of plasma-derived factor VIII and IX preparations, important changes have occurred for hemophilia patients. We studied the medical and social developments over 30 years of hemophilia treatment. Since 1972, 5 cross-sectional national postal surveys among all hemophilia patients in the Netherlands were performed, the latest in 2001. The prestructured questionnaires included items on treatment, the presence of inhibitory antibodies against factor VIII or IX, the annual number of bleeding episodes, use of inpatient hospital care, and hepatitis C and HIV infections. Response rate in 2001 was 70%. Young patients (<16 years) with severe hemophilia showed the largest increase in use of prophylaxis, from 34% in 1972 to 86% in 2001. The occurrence of hemorrhages has gradually decreased. Hospital admissions decreased from 47% of all patients in 1972 to 18% in 2001. Our study shows that the treatment of patients with severe hemophilia in the Netherlands has focused on the use of prophylactic treatment, especially in children. This has resulted in a decrease in bleeding frequency and an improvement of the medical and social circumstances of patients.
Similar articles
-
Inhibitor antibodies to factor VIII and factor IX: management.Semin Thromb Hemost. 2000;26(2):179-88. doi: 10.1055/s-2000-9821. Semin Thromb Hemost. 2000. PMID: 10919411 Review.
-
The management of hemophilia patients with inhibitors.Transfus Med Rev. 1992 Oct;6(4):285-93. doi: 10.1016/s0887-7963(92)70185-0. Transfus Med Rev. 1992. PMID: 1421831 Review. No abstract available.
-
[Management of hemophilia].Rev Prat. 1989 Dec 21;39(30):2669-73. Rev Prat. 1989. PMID: 2515580 French.
-
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.CMAJ. 1995 Jul 15;153(2):147-57. CMAJ. 1995. PMID: 7600466 Free PMC article.
-
Management of hemophilia patients with inhibitors.Hematol Oncol Clin North Am. 1992 Oct;6(5):1035-46. Hematol Oncol Clin North Am. 1992. PMID: 1400071 Review.
Cited by
-
Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019.J Thromb Haemost. 2021 Oct;19(10):2394-2406. doi: 10.1111/jth.15424. Epub 2021 Jul 7. J Thromb Haemost. 2021. PMID: 34117710 Free PMC article.
-
Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Vasc Health Risk Manag. 2010 Mar 3;6:59-68. doi: 10.2147/vhrm.s5217. Vasc Health Risk Manag. 2010. PMID: 20234780 Free PMC article. Review.
-
A feasibility study on two tailored interventions to improve adherence in adults with haemophilia.Pilot Feasibility Stud. 2020 Dec 1;6(1):189. doi: 10.1186/s40814-020-00723-w. Pilot Feasibility Stud. 2020. PMID: 33292771 Free PMC article.
-
Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study.Res Pract Thromb Haemost. 2022 Aug 26;6(6):e12741. doi: 10.1002/rth2.12741. eCollection 2022 Aug. Res Pract Thromb Haemost. 2022. PMID: 36051543 Free PMC article.
-
Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.Blood. 2005 Sep 1;106(5):1552-8. doi: 10.1182/blood-2004-11-4358. Epub 2005 May 10. Blood. 2005. PMID: 15886327 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical